Panasonic's (NASDAQOTH: PCRFY ) not the first company you may think of in the health-care field, but this Japanese electronics maker's a player in blood glucose monitors and other fields. With Panasonic's sales under fire across the board, however, this company's looking to sell off its health-care business to refocus on its core segments. Toshiba (NASDAQOTH: TOSBF ) reportedly has expressed interest in a buy, and private equity-firms are also in the hunt to get on board with Asia's health-care rise.
Buying into the Asian health-care scene isn't anything new. Stryker (NYSE: SYK ) made waves earlier this year by purchasing Chinese spine and trauma firm Trauson for $764 million, and with China's health-care industry still in a state of transition, this is a potent grow opportunity for device firms. But is Panasonic's business worth all that much to buyers? Motley Fool contributor Dan Carroll and health-care analyst Max Macaluso discuss what you need to know in the following video.
Top 10 Transportation Companies For 2016: TeleNav Inc.(TNAV)
TeleNav, Inc. provides personalized navigation and location based services (LBS) in the United States and internationally. It offers GPS Navigator, a voice guided, real time, turn by turn mobile navigation service on a white label basis, such as Sprint Navigation and AT&T Navigator, as well as under the TeleNav brand. The company also provides mobile resource management solutions that allow enterprises to monitor and manage mobile workforces and assets by using its LBS platform to track job status and the location of workers, field assets, and equipment. Its enterprise solutions include TeleNav Track service, as well as TeleNav Vehicle Manager, TeleNav Vehicle Tracker, and TeleNav Asset Tracker. In addition, the company offers mobile navigation services through on-board and connected systems. Further, it focuses on developing LBS to new device platforms, such as tablet devices, as well as new LBS for mobile phones, including location based mobile advertising, commerce, and social networking. The company distributes its services to consumers, wireless carriers, enterprises and automobile manufacturers, and original equipment manufacturers through its wireless carrier partners, as well as through its Web site and mobile phone application stores. TeleNav, Inc. is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By Seth Jayson]
Telenav (Nasdaq: TNAV ) reported earnings on April 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q3), Telenav beat expectations on revenues and beat expectations on earnings per share. - [By Louis Navellier]
Lately, FleetCor has been on a buying spree. This spring, FLT agreed to buy out Telenav’s (TNAV) mobile business — an operation that serves 8,000 business clients by tracking the location of mobile workers in field-based businesses. FleetCor aims to adopt the business to add value to its ongoing fuel card programs.
10 Best Electric Utility Stocks To Buy Right Now: iShares U.S. Aerospace & Defense ETF (ITA)
iShares Dow Jones U.S. Aerospace & Defense Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Aerospace & Defense Index (the Index). The Index measures the performance of the aerospace and defense sector of the United States equity market. Aerospace companies include manufacturers, assemblers and distributors of aircraft and aircraft parts. Defense companies include producers of components and equipment for the defense industry, such as military aircraft, radar equipment and weapons.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. Since all of the securities included in the Index are issued by companies in the aerospace and defense sector, the Fund will be concentrated in the aerospace and defense industry. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Mark Salzinger]
This industry's two largest ETFs��Shares Aerospace and Defense (ITA) and PowerShares Aerospace and Defense (PPA)��ained more than 50% last year.
10 Best Electric Utility Stocks To Buy Right Now: Revive Therapeutics Ltd (RVV)
Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. The Company is also developing a next generation analog of REV-001, which is an improvement of the original compound and it will have the potential to treat new diseases that would otherwise remain untreated with the original compound, such as rare diseases, breathing disorders, and cognitive dysfunction. Advisors' Opinion:- [By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.
10 Best Electric Utility Stocks To Buy Right Now: PHH Corp (PHH)
PHH Corporation (PHH), incorporated in 1953, is an outsource provider of mortgage and fleet management services. PHH operates in three segments: Mortgage Production, Mortgage Servicing and Fleet Management Services. The Company provides mortgage banking services to a range of clients, including financial institutions and real estate brokers, throughout the United States. The Company�� mortgage banking activities include originating, purchasing, selling and servicing mortgage loans through its wholly owned subsidiary, PHH Mortgage Corporation and its subsidiaries (collectively PHH Mortgage). It provides commercial fleet management services to corporate clients and government agencies throughout the United States and Canada through its wholly owned subsidiary, PHH Vehicle Management Services Group LLC (PHH VMS). PHH VMS is a fully integrated provider of fleet management services with a range of product offerings, including managing and leasing vehicle fleets and providing other fee-based services for its clients��vehicle fleets.
Mortgage Production Segment
The Mortgage Production segment provides mortgage services, including private-label mortgage services, to financial institutions and real estate brokers through PHH Mortgage. The Mortgage Production segment generates revenue through fee-based mortgage loan origination services and the origination and sale of mortgage loans into the secondary market. PHH Mortgage generally sells all mortgage loans that it originates to secondary market investors, which include a variety of institutional investors, and typically retains the servicing rights on mortgage loans sold. During the year ended December 31, 2011, 92% of its mortgage loans were sold to, or were sold pursuant to, programs sponsored by Fannie Mae, Freddie Mac or Ginnie Mae and the remaining 8% were sold to private investors. The Mortgage Production segment includes PHH Home Loans, LLC (together with its subsidiaries, PHH Home Loans), which is a joint venture that the C! ompany maintains with Realogy Corporation. The Company owns 50.1% of PHH Home Loans through its subsidiaries and Realogy owns the remaining 49.9% through their affiliates. PHH has rights to use the Century 21, Coldwell Banker and ERA brand names in marketing its mortgage loan products through PHH Home Loans and other arrangements that it has with Realogy.
The Mortgage Production segment also includes its interest in Speedy Title & Appraisal Review Services LLC (STARS), which provides appraisal services utilizing a network of professional licensed firms offering local coverage throughout the United States and also provides credit research, flood certification and tax services. On March 31, 2011, it sold 50.1% of the interests in STARS to CoreLogic, Inc. The Company operates through two principal business channels: private label services and real estate.
The retail platform consists of private label services and real estate channels. The Company is a provider of private-label mortgage loan originations for financial institutions and other entities throughout the United States. In this channel, the Company offers a complete outsourcing solution, from processing applications through funding, for clients that wish to offer mortgage services to their customers but are not equipped to handle all aspects of the process cost-effectively. The Company also purchases closed mortgage loans from financial institutions.
The Company works with real estate brokers to provide their customers with mortgage loans. Through its affiliations with real estate brokers, it has access to home buyers at the time of purchase. It works with brokers associated with NRT Incorporated, Realogy�� owned real estate brokerage business, brokers associated with Realogy�� franchised brokerages (Realogy Franchisees) and third-party brokers that are not affiliated with Realogy. During 2011, approximately 22% of the Company�� mortgage loan originations were derived from its relationship with Realogy ! and its a! ffiliates. In this channel, it also works with Cartus Corporation, Realogy�� relocation business, to provide mortgage loans to employees of Cartus��clients. Cartus provides outsourced corporate relocation services in the United States. Realogy has agreed that the real estate brokerage business owned and operated by NRT Incorporated and the title and settlement services business owned and operated by Title Resource Group LLC will recommend PHH Home Loans as provider of mortgage loans to the independent sales associates affiliated with Realogy, excluding the independent sales associates of any Realogy Franchisee, and all customers of Realogy Services Group LLC and Realogy Services Venture Partner, Inc., excluding Realogy Franchisees. Certain Realogy Franchisees have agreed to recommend PHH Mortgage as provider of mortgage loans to their respective independent sales associates. As of 2011, it has entered into exclusive marketing service agreements with 5% of Realogy Franchisees. In the Relocation Channel, the Company works with Cartus Corporation, Realogy�� relocation business, to provide mortgage loans to employees of Cartus��clients.
During 2011, the Company originated mortgage loans for approximately 17% of the transactions in which real estate brokerages owned by Realogy represented the home buyer. And approximately 8% of the transactions in which real estate brokerages franchised by Realogy where it had exclusive marketing service agreements, represented the home buyer.
Mortgage Servicing Segment
The Company principally generates revenue in its Mortgage Servicing segment through fees earned from its servicing rights or from its subservicing agreements. Mortgage servicing rights are the rights to receive a portion of the interest coupon and fees collected from the mortgagors for performing specified mortgage servicing activities, which consist of collecting loan payments, remitting principal and interest payments to investors, managing escrow funds for th! e payment! of mortgage-related expenses, such as taxes and insurance, performing loss mitigation activities on behalf of investors, and otherwise administering its mortgage loan servicing portfolio. Mortgage servicing rights for sold loans are initially recorded at fair value in its Mortgage Production Segment�� results of operations. Changes in fair value subsequent to the initial capitalization are recorded in its Mortgage Servicing Segment�� results of operations. The Company�� Mortgage Servicing segment also includes the results of its reinsurance activities from its wholly owned subsidiary, Atrium Reinsurance Corporation.
The Company provides mortgage reinsurance to certain third-party insurance companies that provide primary mortgage insurance on loans originated in its Mortgage Production segment. While it does not underwrite primary mortgage insurance directly, it provides reinsurance that covers losses in excess of a specified percentage of the principal balance of a given pool of mortgage loans, subject to a contractual limit. In exchange for assuming a portion of the risk of loss related to the reinsured loans, Atrium Reinsurance Corporation, its wholly owned subsidiary, receives a portion of borrower�� premiums from the third-party insurance companies.
Fleet Management Services Segment
The Company provides fleet management services to corporate clients and government agencies throughout the United States and Canada. It is an integrated provider of these services with a range of product offerings. The Company primarily focuses on clients with fleets of greater than 75 vehicles. As of 2011, it had approximately 270,000 vehicles leased, primarily consisting of cars and light-duty trucks and, to a lesser extent, medium and heavy-duty trucks, trailers and equipment, and approximately 300,000 additional vehicles serviced under fuel cards, maintenance cards, accident management services arrangements and/or similar arrangements. During 2011, the Company purchas! ed approx! imately 61,000 vehicles.
The Company provides corporate clients and government agencies with services and products, such as Fleet Leasing and Fleet Management Services, Maintenance Services, Accident Management Services, and Fuel Card Services. The Fleet Leasing and Fleet management services include vehicle leasing, fleet policy analysis and recommendations, benchmarking, vehicle recommendations, ordering and purchasing vehicles, arranging for vehicle delivery and administration of the title and registration process, as well as tax and insurance requirements, pursuing warranty claims and remarketing used vehicles. It leases vehicles to its clients under both open-end and closed-end leases. Open-end leases represent 97% of its lease portfolio, and are a form of lease in which the client bears substantially all of the vehicle�� residual value risk. These leases typically have a minimum term of 12 months, and can be continued after that at the lessee�� election for successive monthly renewals. Upon return of the vehicle by the lessee, it typically sells the vehicle into the secondary market, and the client receives a credit or pays the difference between the sale proceeds and the vehicle�� book value.
Open-end leases may be classified as operating or direct financing depending upon the nature of the residual guarantee. Revenues for operating leases contain a depreciation component, an interest component and a management fee component, and are recognized over the lease term. For direct financing leases, revenues contain an interest component and a management fee component, and are recognized over the lease term. Closed-end leases represent 3% of its lease portfolio, and are a form of lease in which it retains the residual risk of the value of the vehicle at the end of the lease term. Closed-end leases may be classified as operating or direct financing based on the terms of the individual contracts.
The Company offers clients vehicle maintenance service cards that! are used! to facilitate payment for repairs and maintenance. It maintains a network of third-party service providers in the United States and Canada to ensure ease of use by the clients drivers. The vehicle maintenance service cards provide clients with negotiated discounts off of full retail prices through its supplier network, access to its in-house team of certified maintenance experts that monitor transactions for policy compliance, reasonability and cost-effectiveness, and inclusion of vehicle maintenance transactions in a consolidated information and billing database, which assists clients with the evaluation of overall fleet performance and costs. During 2011, the Company averaged 324,000 maintenance service cards in the United States and Canada. It receives a fixed monthly fee for these services from its clients, as well as additional fees from service providers in its third-party network for individual maintenance services.
PHH provides its clients with accident management services, such as immediate assistance upon receiving the initial accident report from the driver, an organized vehicle appraisal and repair process through a network of third-party preferred repair and body shops and coordination and negotiation of potential accident claims. The Company�� accident management services provide its clients with convenient, coordinated 24-hour assistance from its call center, access to its relationships with the repair and body shops included in its preferred supplier network, which typically provide clients with favorable terms, and expertise of its damage specialists, who ensure that vehicle appraisals and repairs are appropriate, cost-efficient and in accordance with each client�� specific repair policy. During 2011, it averaged 298,000 vehicles that were participating in accident management programs. The Company receives fees from its clients for these services, as well as additional fees from service providers in its third-party network for individual incident services.
It prov! ides its clients with fuel card programs that facilitate the payment, monitoring and control of fuel purchases. Fuel is typically the single fleet-related operating expense. Its fuel cards provide its clients with access to more fuel brands and outlets than other private-label corporate fuel cards, point-of-sale processing technology for fuel card transactions that enhances clients��ability to monitor purchases and consolidated billing, and access to other information on fuel card transactions, which assists clients with the evaluation of overall fleet performance and costs. Its fuel cards are offered through relationships with third parties in the United States, and a card in Canada, which offer expanded fuel management capabilities on one service card. During 2011, it averaged 295,000 fuel cards in the United States and Canada. PHH receives both monthly fees from its fuel card clients and additional fees from fuel partners and providers.The Company competes with Bank of America, Wells Fargo Home Mortgage, Chase Home Finance, CitiMortgage, GE Commercial Finance Fleet Services, Wheels, Inc., Automotive Resources International and Lease Plan International.
Advisors' Opinion:- [By Jon C. Ogg]
PHH Corp. (NYSE: PHH) was downgraded to Market Perform from Outperform at Keefe Bruyette & Woods.
T-Mobile US Inc. (NYSE: TMUS) was started as Outperform at Cowen & Co.
10 Best Electric Utility Stocks To Buy Right Now: Gentherm Inc (THRM)
Gentherm Inc, formerly Amerigon Incorporated, doing business as Gentherm, incorporated in 1991, is a global developer and marketer of thermal management technologies for a range of heating and cooling and temperature control applications. Automotive products include actively heated and cooled seat systems and cup holders, heated and ventilated seat systems, thermal storage bins, heated seat and steering wheel systems, cable systems and other electronic devices. The Company is developing materials for thermoelectrics and systems for waste heat recovery and electrical power generation for the automotive market that may have applications for consumer products, as well as industrial and technology markets. Gentherm has facilities in the United States, Germany, Mexico, China, Canada, Japan, England, Korea, Malta, Hungary and the Ukraine. In February 2013, it announced the closing of the acquisition of W.E.T. Automotive Systems AG (W.E.T.).
The Company designs, develops and markets products based on its thermoelectric device (TED) technologies for a range of global markets and heating and cooling applications. As of December 31, 2011, its principal product was its Climate Control Seat (CCS), which it sells to automobile and light truck original equipment manufacturers or their tier one suppliers. The Company�� CCS product is offered as an optional or standard feature on automobile models produced by Ford Motor Company, General Motors, Toyota Motor Corporation, Nissan, Tata Motors, Ltd. and Hyundai. On May 16, 2011 the Company, through its wholly owned subsidiary Amerigon Europe, GmbH (Amerigon Europe), acquired a majority interest in W.E.T. Automotive Systems AG. (W.E.T.).
Thermoelectric device
The Company�� products are primarily based upon its TED technology. A TED is a solid state circuit that has the capability to produce both a hot and cold thermal condition. TEDs also have a capability known as the Seebeck effect that is reciprocal to the Peltier effect.
Climate Control Seat
The Company�� CCS product uses one or more TEDs, which generate heating or cooling depending upon the direction of the current applied to the device. If a manufacturer wishes to integrate its CCS product into a seat, it provides the Company with automotive seats to be modified so that it can install a unit in a prototype. The seat is then returned to the manufacturer for evaluation and testing. If a manufacturer accepts the Company�� CCS product, a program can then be launched for a particular model on a production basis.
Heated and Ventilated Seat
The Company sells a heated and ventilated only variant of the CCS. This product works in a similar fashion to its CCS, only there is no active cooling capability and no TED. In the cooling mode, the vent only system will use the ambient cabin air to provide a degree of cooling comfort to the seat occupant. In the heating mode, the vent only system is supplemented with more traditional resistive heating elements. Similarly, W.E.T.�� core seat comfort product uses a resistive element heater mat to generate heat when the seat is in heating mode and ambient cabin air for cooling.
Heated and Cooled Cup Holder
The heated and cooled cup holder represents an adaptation of the technology found in its CCS, including the use of a TED and other key elements. The dual cup holder provides separate temperature settings in each holder allowing the driver and passenger to individually maintain a heated or cooled beverage. The vehicles that feature the heated and cooled cup holder was the 2011 Dodge Charger and 2011 Chrysler 300 during the year ended December 31, 2011.
Heated and Cooled Mattress
The Company�� heated and cooled mattress incorporates its Climate Control Sleep System (CCSS) technology. The mattress is sold in the United States by its retail partner, Mattress Firm, under its YuMe brand. Mattress Firm has over 800 retail stores located a! cross 26 ! states. There are five available settings in each of the heat and cool modes, as well as an ambient setting. The bed can be controlled using either the Master Control Unit (MCU) or one of two remotes provided for each zone.
Automotive Cable Systems
W.E.T. produces automotive cable systems to be used to connect automotive components to sources of power. W.E.T.�� cable systems include both ready-made individual cables and ready-to-install cable networks.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Gentherm (Nasdaq: THRM ) , whose recent revenue and earnings are plotted below.
10 Best Electric Utility Stocks To Buy Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Ernie Tremblay, Biosciences Specialist, Money Morning | January 17, 2014 · ]
When I'm setting out in search of a lucrative bioscience stock, here are some qualities I find really attractive:
Market cap. $250M-$2.5B. This is the sweet spot for growth. Less than $250M can mean low volume trading, which can be a problem if you need to sell. More than $2.5B makes a company less responsive to catalysts. Single product pipeline. These companies can yield high returns because they carry high risk. If their drug succeeds, their investors can get rich rapidly. A failure, however, can mean doom, so you need to know what you're doing in evaluating the drug's potential to be effective, safe, convincing to the FDA, and marketable. Some of my recommendations, of course, are for companies that have richer pipelines. They yield less return, but they're safer bets for a balanced portfolio. An upcoming catalyst. A catalyst, such as an AdCom, FDA approval date (called a PDUFA), or even results from a clinical trial, can make you a whole lot richer overnight. Last year, Sarepta Therapeutics (Nasdaq: SRPT) tripled its stock price overnight when the company announced positive results for a study of its Duchenne muscular dystrophy drug. Orphan drug status. As I explained above, these drug candidates have real advantages over traditional "blockbuster" entries. An extreme need. Everyone born with HoFH would eventually die from it, and before Aegerion's Juxtapid (lomitapide), no effective treatment existed. Patients were longing for it. Little or no competition. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS), in partnership with Genzyme Pharmaceuticals, was developing a drug, mimoperson, to compete with Juxtapid, but it was inferior in several ways (injectable rather than oral, more severe side effects). It also passed its AdCom, but barely, garnering a vote of 9 to 6. Juxtapid had a nearly clear field to play in. The Profits AheadNext, of course, comes the tricky part. You've got to be able to read studies on exper
- [By Keith Speights]
On the other hand
The good news is that biotech investors who don't meet the above criteria can often see solid returns. I think Sarepta Therapeutics (NASDAQ: SRPT ) offers a nice opportunity right now. - [By Grace L. Williams]
Sarepta Therapeutics (SRPT) saw its director Anthony Chase buy 10,000 shares for $385,000. Sarepta saw a slight uptick in share price around this time after it announced positive results in a Phase 2b extension study involving the use of eteplirsen as a treatment for patients with Duchenne muscular dystrophy.
- [By Jake L'Ecuyer]
Sarepta Therapeutics (NASDAQ: SRPT) tumbled 11.94 percent to $18.00 after Citigroup downgraded the stock from Neutral to Sell.
First Solar (NASDAQ: FSLR) was down, falling 9.45 percent to $51.38 after Goldman Sachs downgraded the stock from Buy to Sell.
10 Best Electric Utility Stocks To Buy Right Now: Fomento Economico Mexicano SAB de CV (FOMC)
Fomento Economico Mexicano SAB de CV (FEMSA) is a Mexico-based holding company engaged in the beverages industry. Through its subsidiary Coca-Cola FEMSA SAB de CV, the Company is active in the production and distribution of a variety of non-alcoholic beverages, bottled water and still beverages such brands as Coca-Cola, Fanta, Sprite, Powerade, Delaware Punch and other trademark beverages of The Coca-Cola Company in Mexico. Through FEMSA Comercio SA de CV, it operates the OXXO convenience-store chain in Latin America. The Company operates in a number of Latinamerican countries and in Philippines. Advisors' Opinion:- [By Canadian Value]
Also interesting is that the duration of rising rate environments is distinctly shorter after 1982. The average duration declines to 14 months from 40 months prior to 1982. A possible explanation could be changes in the monetary mechanism influencing interest rates. In 1982, the Federal Open Market Committee (FOMC) first referenced a targeted federal funds rate.7
No comments:
Post a Comment